Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04093349
Other study ID # SPK-3006-101
Secondary ID 2019-001283-30
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 1, 2020
Est. completion date April 2032

Study information

Verified date October 2023
Source Spark Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease receiving enzyme replacement therapy (ERT). Participants will be treated in sequential, dose-level cohorts.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4
Est. completion date April 2032
Est. primary completion date April 2032
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Provide written informed consent; - Males and Females =18 years of age with late-onset Pompe disease; - Received ERT for at least the previous 24 months - Have clinically moderate, late-onset Pompe disease characteristics; - Agree to use reliable contraception. Exclusion Criteria: - Active hepatitis B and/or C; - Significant underlying liver disease; - Human immunodeficiency virus (HIV) infection; - Prior hypersensitivity to rhGAA; - Pre-existing anti-AAV neutralizing antibody titers; - High titer antibody responses to rhGAA; - Requires any invasive ventilation or requires noninvasive ventilation while awake and upright; - Received any prior vector or gene transfer agent; - Active malignancy (except non-melanoma skin cancer); - History of liver cancer; - Pregnant or nursing women; - Any evidence of active infection at the time of SPK-3006 infusion.

Study Design


Intervention

Genetic:
SPK-3006
adeno-associated viral (AAV) vector

Locations

Country Name City State
Canada Montreal Neurological Hospital Montréal Quebec
Canada The Ottawa Hospital Ottawa Ontario
Canada Vancouver General Hospital Vancouver British Columbia
Denmark Rigshospitalet Copenhagen
France Centre Hospitalier Universitaire d'Angers Angers
France CHU Paris IdF Ouest - Hôpital Raymond Poincaré Garches
France Centre Hospitalier Régional Universitaire de Lille Lille Cedex
France Assistance Publique Hôpitaux de Marseille Marseille
France Nice University Hospital Nice
Germany Friedrich-Baur-Institut Neurologische Klinik Ludwig-Maximilians-Universität München Munchen
Italy Universita Degli Studi Di Messina - Dipartimento di Medicina Clinica e Sperimentale Messina
Italy Universita Degli Studi Di Milano, Laboratorio di Biochimica e Genetica della Malattie Neuromuscolari Milano
Italy Malattie Metaboliche Universita Degli Studi Di Napoli Federico II Naples
Italy UO Neurologia Azienda Ospedaliera Universitaria Pisana Pisa
Italy Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino - Neurology, Osp. Molinette Torino
Netherlands Erasmus Medical Center Rotterdam
United Kingdom New Queen Elizabeth Hospital Birmingham Birmingham GBR
United Kingdom The Royal Free London NHS Foundation Trust London GBR
United Kingdom Salford Royal MHS Foundation Trust Salford
United States Emory University School of Medicine Atlanta Georgia
United States Lysosomal and Rare Disorders Research & Treatment Center Fairfax Virginia
United States University of Kansas Medical Center Research Institute Kansas City Kansas
United States University of Minnesota Minneapolis Minnesota
United States University of California Irvine Health Orange California
United States University of Pennsylvania Philadelphia Pennsylvania
United States Barrow Neurological Institute Phoenix Arizona
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Spark Therapeutics

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  France,  Germany,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of adverse and serious adverse events (AEs/SAEs), including clinically significant abnormal laboratory values. Adverse events. Up to 5 years
Primary Occurrence of immune response against AAV capsid Up to 5 years
Primary Occurrence of immune response against GAA transgene Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT01942590 - Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Phase 1/Phase 2
Not yet recruiting NCT01409486 - Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry N/A
Completed NCT00976352 - Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease Phase 1/Phase 2
Recruiting NCT01665326 - Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
Completed NCT01758354 - Newborn Screening Assay of Pompe's Disease N/A
Recruiting NCT00231400 - Pompe Disease Registry Protocol
Recruiting NCT04476550 - Clinical Specimen Collection From Pompe Disease Patients
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT01380743 - Drug-drug Interaction Study Phase 2
Recruiting NCT05734521 - Avalglucosidase Alfa Pregnancy Study
Completed NCT02742298 - Pompe Disease QMUS and EIM N/A
Terminated NCT02185651 - A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction Phase 1
Completed NCT02654886 - Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease. N/A
Completed NCT02405598 - Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease Phase 4
Completed NCT00701129 - An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Phase 4
Completed NCT01451879 - Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies N/A
Completed NCT02240407 - Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease Phase 1
Completed NCT05073783 - A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
Completed NCT02363153 - Diet and Exercise in Pompe Disease N/A
Completed NCT01410890 - Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease Phase 4

External Links